Skip to main content

Greenberg Traurig Advises Micron Biomedical in Negotiations with Bill & Melinda Gates Foundation

 Life Sciences Company Receives $23.6 Million Grant

ATLANTA – Nov. 28, 2023 – Greenberg Traurig, LLP advised Micron Biomedical in negotiations with the Bill & Melinda Gates Foundation, which awarded the life sciences company a $23.6 million grant to accelerate the mass production of needle-free vaccines utilizing Micron’s proprietary technology.

The Atlanta-based company will use the grant to increase its manufacturing capacity for a measles-rubella vaccine based on its microarray technology which makes administering the vaccine virtually pain-free for children, according to its release. The new technolgy also reduces the need for cold chain distribution, so the vaccine could be more accessible in developing countries. In 2017, the foundation provided Micron with a grant to fund the first clinical trial of its microarray technology involving children.

The Greenberg Traurig team advising Micron was led by Wayne H. Elowe, shareholder and co-chair of the firm’s global Life Sciences and Medical Technology Practice and co-chair of the Atlanta Corporate practice. Atlanta-based Corporate Associate William H. Grossenbacher III also worked on this transaction.

About Greenberg Traurig: Greenberg Traurig, LLP has more than 2650 attorneys in 47 locations in the United States, Europe and the Middle East, Latin America, and Asia. The firm is a 2022 BTI “Highly Recommended Law Firm” for superior client service and is consistently among the top firms on the Am Law Global 100 and NLJ 500. Greenberg Traurig is Mansfield Rule 6.0 Certified Plus by The Diversity Lab. The firm is recognized for powering its U.S. offices with 100% renewable energy as certified by the Center for Resource Solutions Green-e® Energy program and is a member of the U.S. EPA’s Green Power Partnership Program. The firm is known for its philanthropic giving, innovation, diversity, and pro bono. Web: